Iron administration did not increase the mortality risk of hemodialysis patients with cancer, but the safety of increasing ESA doses was not confirmed.
An analysis of more than 800 IgAN patients treated from 2002-2021 provides an overview of factors associated with anemia as well as its impact on prognosis.